JeffreyHMulerMD

Oncology • Sylvania, OH

Physician

Join to view full profile

Are you Dr. Muler?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 71 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
5308 Harroun Rd
Suite 055
Sylvania, OH 43560
Phone+1 419-824-6599

Fax+1 419-885-3870

Summary

Dr. Jeffrey Muler, MD is an oncologist in Sylvania, Ohio. He is currently licensed to practice medicine in Ohio, Massachusetts, and Indiana. He is affiliated with ProMedica Toledo Hospital, Mercy Health - St. Vincent Medical Center, and St. Luke's Hospital.

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2000 - 2003
University of MichiganResidency, Internal Medicine, 1996 - 1999
Tufts University School of MedicineClass of 1996

Certifications & Licensure

MA State Medical License 2017 - 2026
OH State Medical License 1999 - 2026
VA State Medical License 1999 - 2026
IN State Medical License 1999 - 2025
MI State Medical License 1999 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Aug 27
Completed
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

47 citations
Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Mark M. Zalupski, Cathryn Rankin, James R. Ryan, David R. Lucas, Jeffrey Muler
Cancer. 2004-02-15
73 citations
Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer
Jeffrey H. Muler, Cornelius J. McGinn, Daniel P. Normolle, Theodore Lawrence, Diane Brown
Journal of Clinical Oncology. 2004-01-15
10 citations
Gastrointestinal stromal tumors: chemotherapy and imatinib.
Jeffrey H. Muler, Laurence H. Baker, Mark M. Zalupski
Current Oncology Reports. 2002-11-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member